|
A prospective phase II/III study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A subanalysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging. |
|
|
Stock and Other Ownership Interests - Adient Medical; Bronx Medical Center; Verix |
Consulting or Advisory Role - Adient Medical; Verix |
Patents, Royalties, Other Intellectual Property - Patent disclosures, provisionals submitted for instrument to analyze biopsy specimens (unrelated to the small renal masses topic). Patent holder for device related to x-ray imaging data collection (unrelated to small renal masses topic)....July 2008. |
Travel, Accommodations, Expenses - Verix |
Other Relationship - Society of Interventional Radiology Foundation |
(OPTIONAL) Uncompensated Relationships - Society of Interventional Radiology Foundation |
|
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck; Pfizer |
Research Funding - Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Harpoon Therapeutics (Inst); Janssen (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); Progenics (Inst); Progenics (Inst); Prometheus (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck |
|
|
No Relationships to Disclose |
|
|
Honoraria - Abbvie; Amgen; Astellas Pharma; Bayer; Genzyme; Janssen; Pfizer; Sanofi |
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Genzyme; Janssen; Pfizer; Progenics; Sanofi |
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Sanofi |
Research Funding - Astellas Pharma; AstraZeneca; Janssen; Sanofi |
Patents, Royalties, Other Intellectual Property - Transcriptional system and uses therof for single cell detection |
Other Relationship - Merck; Progenics |
|
|
Research Funding - Progenics (Inst) |
|
|
No Relationships to Disclose |
|
|
Leadership - CUE Biopharma |
Stock and Other Ownership Interests - CUE Biopharma; GreenMark Biomedical; Medsyn Biopharma; Oncopia Therapeutics |
Honoraria - Johnson & Johnson; Progenics |
Consulting or Advisory Role - Akrevia Therapeutics; Clinomics; CUE Biopharma; GloriousMed Technology |
Research Funding - Progenics |
Travel, Accommodations, Expenses - CUE Biopharma |
|
|
Stock and Other Ownership Interests - Precision Molecular |
Research Funding - Progenics |
Travel, Accommodations, Expenses - Progenics |
|
|
Stock and Other Ownership Interests - Gilead Sciences; Roche/Genentech |
Honoraria - Exelixis; Jounce Therapeutics; Merck; Prime Oncology |
Consulting or Advisory Role - Exelixis; Gerson Lehrman Group; Guidepoint Pharmacy; Jounce Therapeutics |
Research Funding - Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Progenics (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Exelixis; Prime Oncology |
|
|
Stock and Other Ownership Interests - Endocyte; Johnson & Johnson; Pfizer |
Honoraria - Advanced Accelerator Applications; Bayer; Isologic |
Consulting or Advisory Role - Advanced Accelerator Applications; Bayer |
Research Funding - Bayer (Inst); Progenics (Inst) |
Travel, Accommodations, Expenses - Advanced Accelerator Applications; Bayer |
|
|
|
Stock and Other Ownership Interests - Progenics |
|
|
No Relationships to Disclose |
|
|
|
|
Stock and Other Ownership Interests - Progenics |
|
|
|
Consulting or Advisory Role - AVID Radiopharmaceuticals; Curium Pharma; GE Healthcare; ImaginAb; Progenics |
Research Funding - Blue Earth Diagnostics (Inst); ImaginAb (Inst); Progenics (Inst) |
Travel, Accommodations, Expenses - Blue Earth Diagnostics; ImaginAb; Progenics; Siemens (I) |
|
|
Consulting or Advisory Role - Advanced Accelerator Applications; Astellas Pharma; Bayer; Curium Pharma; Curium Pharma; Endocyte; Johnson & Johnson; ORIC Pharmaceuticals |
Research Funding - Bayer (Inst); Corcept Therapeutics (Inst); Endocyte (Inst); Janssen (Inst); Progenics (Inst); Roche/Genentech (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Endocyte; Fujifilm |